Although the prevalence of those receiving treatment for IGT was significantly higher in males with MS than in females with MS, there was no significant difference in the prevalence of FL with ALT elevation between genders with MS in those receiving treatment for IGT. The gene discussed is GPT; the disease is myeloid sarcoma.